Novo Nordisk Has a Fresh New Name -- but It Still Faces the Same Old Problems

Novo Nordisk is rebranding to 'Novo' as it launches a pill version of its GLP-1 weight-loss drug to regain market share lost to Eli Lilly. While the company has a solid strategy with low pricing to drive volume, the name change alone won't address fundamental competitive challenges. The stock is down 70% from its 2024 high, though it trades at an attractive valuation with a 4.1% dividend yield.